Benralizumab Efficacy for Patients with Fixed Airflow Obstruction and Severe, Uncontrolled Eosinophilic Asthma

Fixed airflow obstruction (FAO) is present for approximately 16% of patients with asthma, with a greater FAO incidence for patients with severe disease than for those with less severe disease.1,2 Patients with FAO have increased exacerbation frequency, decreased lung function, and greater mortality than patients without FAO.3,4 The risk of developing FAO is 2 –4-fold greater for patients with increased sputum/blood eosinophil counts than for those with lesser eosinophil counts.3–7 Elevated sputum and/or blood eosinophil counts are consensual markers of asthma with an eosinophilic phenotype.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research